Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) FCF Margin (2016 - 2025)

Arcadia Biosciences filings provide 12 years of FCF Margin readings, the most recent being 93.12% for Q4 2025.

  • On a quarterly basis, FCF Margin rose 8632.0% to 93.12% in Q4 2025 year-over-year; TTM through Dec 2025 was 97.55%, a 9302.0% increase, with the full-year FY2025 number at 97.55%, up 9305.0% from a year prior.
  • FCF Margin hit 93.12% in Q4 2025 for Arcadia Biosciences, down from 23.04% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 41.38% in Q4 2022 to a low of 627.05% in Q1 2021.
  • Median FCF Margin over the past 5 years was 168.19% (2021), compared with a mean of 207.91%.
  • Biggest five-year swings in FCF Margin: surged 293482bps in 2021 and later plummeted -57561bps in 2023.
  • Arcadia Biosciences' FCF Margin stood at 156.93% in 2021, then soared by 126bps to 41.38% in 2022, then crashed by -1391bps to 534.23% in 2023, then soared by 66bps to 179.44% in 2024, then skyrocketed by 48bps to 93.12% in 2025.
  • The last three reported values for FCF Margin were 93.12% (Q4 2025), 23.04% (Q3 2025), and 138.28% (Q2 2025) per Business Quant data.